Figure 5 | Scientific Reports

Figure 5

From: A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytes

Figure 5

EYE-502 suppresses CNV formation and reduces pericyte coverage. (A,B) The mice received intravitreal injections of PBS, 0.1% DMSO, EYE-502 (50 μM), or aflibercept for 14 days following laser photocoagulation. The group treated with PBS was taken as the Ctrl group. RPE/choroid complexes were prepared for Isolectin-B4 staining and evaluation of CNV area. Dashed lines delineate the lesions. Scale bar, 100 μm (A, n = 10). Pericyte coverage was quantified by staining RPE-choroidal flat mounts with Isolectin-B4 and NG2. Scale bar, 50 μm (B, n = 6). *P < 0.05 versus Ctrl group; Kruskal–Wallis’s test followed by Bonferroni’s post hoc test.

Back to article page